ATE403656T1 - Xanthinderivate als a2b- adenosinrezeptorantagonisten - Google Patents
Xanthinderivate als a2b- adenosinrezeptorantagonistenInfo
- Publication number
- ATE403656T1 ATE403656T1 AT03817096T AT03817096T ATE403656T1 AT E403656 T1 ATE403656 T1 AT E403656T1 AT 03817096 T AT03817096 T AT 03817096T AT 03817096 T AT03817096 T AT 03817096T AT E403656 T1 ATE403656 T1 AT E403656T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- adenosine receptor
- xanthine derivatives
- xanthine
- derivatives
- Prior art date
Links
- 101150078577 Adora2b gene Proteins 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/014085 WO2004106337A1 (en) | 2003-05-06 | 2003-05-06 | Xanthine derivatives as a2b adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE403656T1 true ATE403656T1 (de) | 2008-08-15 |
Family
ID=33488737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03817096T ATE403656T1 (de) | 2003-05-06 | 2003-05-06 | Xanthinderivate als a2b- adenosinrezeptorantagonisten |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1622908B1 (de) |
| JP (1) | JP2006515316A (de) |
| CN (1) | CN100590125C (de) |
| AT (1) | ATE403656T1 (de) |
| AU (1) | AU2003249604B2 (de) |
| CA (1) | CA2524778C (de) |
| CY (1) | CY1108457T1 (de) |
| DE (1) | DE60322748D1 (de) |
| DK (1) | DK1622908T3 (de) |
| ES (1) | ES2311759T3 (de) |
| HK (1) | HK1092137A1 (de) |
| MX (1) | MXPA05011860A (de) |
| NZ (1) | NZ543416A (de) |
| PT (1) | PT1622908E (de) |
| SI (1) | SI1622908T1 (de) |
| WO (1) | WO2004106337A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2612344A1 (en) | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| JP2009528389A (ja) * | 2006-03-02 | 2009-08-06 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ａアデノシン受容体拮抗剤 |
| WO2009088518A1 (en) * | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
| US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
| JP5460690B2 (ja) * | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
| WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
| AU2010222289B2 (en) | 2009-03-13 | 2013-07-11 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| WO2011055391A1 (en) | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| CA2810625C (en) * | 2010-09-13 | 2018-01-23 | Advinus Therapeutics Private Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| RS56066B2 (sr) | 2013-03-15 | 2018-09-28 | Hydra Biosciences Inc | Supstituisani ksantini i postupci za njihovu upotrebu |
| ES2580702B1 (es) | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
| EP3389664A4 (de) * | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | Koffeininhibitoren von mthfd2 und verwendungen dafür |
| WO2018204661A1 (en) * | 2017-05-05 | 2018-11-08 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| EP4364727A3 (de) * | 2018-03-05 | 2024-05-15 | Teon Therapeutics, Inc. | Adenosinrezeptorantagonisten und verwendungen davon |
| CA3126735A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| CN118459463B (zh) * | 2024-07-10 | 2024-09-06 | 山东中医药大学附属医院 | 一种化合物及其制备方法和治疗2型糖尿病的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8510758D0 (en) * | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| WO1995011681A1 (en) * | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| DE19535504A1 (de) * | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| ATE234099T1 (de) * | 1998-04-24 | 2003-03-15 | Leuven K U Res & Dev | Immununterdrückende effekte von 8 substituierten xanthinderivaten |
| US6545002B1 (en) * | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| DE60206756T2 (de) * | 2001-06-29 | 2006-07-13 | CV Therapeutics, Inc., Palo Alto | Purin derivate als a2b adenosin rezeptor antagonisten |
| CA2466477C (en) * | 2001-11-09 | 2012-10-02 | Rao Kalla | A2b adenosine receptor antagonists |
| MXPA03008967A (es) * | 2002-02-01 | 2004-02-12 | King Pharmaceuticals Res & Dev | Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b. |
-
2003
- 2003-05-06 AU AU2003249604A patent/AU2003249604B2/en not_active Ceased
- 2003-05-06 JP JP2005500296A patent/JP2006515316A/ja active Pending
- 2003-05-06 NZ NZ543416A patent/NZ543416A/en not_active IP Right Cessation
- 2003-05-06 CN CN03826411A patent/CN100590125C/zh not_active Expired - Fee Related
- 2003-05-06 MX MXPA05011860A patent/MXPA05011860A/es active IP Right Grant
- 2003-05-06 AT AT03817096T patent/ATE403656T1/de active
- 2003-05-06 ES ES03817096T patent/ES2311759T3/es not_active Expired - Lifetime
- 2003-05-06 DK DK03817096T patent/DK1622908T3/da active
- 2003-05-06 EP EP03817096A patent/EP1622908B1/de not_active Expired - Lifetime
- 2003-05-06 SI SI200331355T patent/SI1622908T1/sl unknown
- 2003-05-06 WO PCT/US2003/014085 patent/WO2004106337A1/en active Application Filing
- 2003-05-06 PT PT03817096T patent/PT1622908E/pt unknown
- 2003-05-06 DE DE60322748T patent/DE60322748D1/de not_active Expired - Lifetime
- 2003-05-06 CA CA2524778A patent/CA2524778C/en not_active Expired - Fee Related
-
2006
- 2006-08-07 HK HK06108745.5A patent/HK1092137A1/xx not_active IP Right Cessation
-
2008
- 2008-10-27 CY CY20081101212T patent/CY1108457T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003249604A1 (en) | 2005-01-21 |
| CY1108457T1 (el) | 2014-04-09 |
| CA2524778A1 (en) | 2004-12-09 |
| ES2311759T3 (es) | 2009-02-16 |
| AU2003249604B2 (en) | 2011-06-30 |
| SI1622908T1 (sl) | 2008-12-31 |
| CA2524778C (en) | 2013-01-29 |
| NZ543416A (en) | 2009-01-31 |
| CN1771250A (zh) | 2006-05-10 |
| CN100590125C (zh) | 2010-02-17 |
| DE60322748D1 (de) | 2008-09-18 |
| DK1622908T3 (da) | 2008-11-17 |
| JP2006515316A (ja) | 2006-05-25 |
| MXPA05011860A (es) | 2006-02-17 |
| PT1622908E (pt) | 2008-11-14 |
| EP1622908A1 (de) | 2006-02-08 |
| HK1092137A1 (en) | 2007-02-02 |
| EP1622908B1 (de) | 2008-08-06 |
| WO2004106337A1 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1092137A1 (en) | Xanthine derivatives as a2b adenosine receptor antagonists | |
| ATE461932T1 (de) | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors | |
| WO2003042214A3 (en) | A2b adenosine receptor antagonists | |
| ATE387446T1 (de) | Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren | |
| SMP200600024B (it) | 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina | |
| ATE384053T1 (de) | Triazolderivate als tachykininrezeptor- antagonisten | |
| DE122012000043I1 (de) | Pyrrolo[2,3-B]pyridinderivate als proteinkinaseinhibitoren. | |
| ATE538123T1 (de) | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors | |
| DE60313872D1 (de) | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen | |
| CY2013006I2 (el) | Ετεροαρυλο υποκατεστημενες πυρρολο[2,3-b]πυριδινες και πυρρολο[2,3-b]πυριμιδινες ως αναστολεις κινασης janus | |
| DK2272517T3 (da) | Orto-kondenserede pyridin- og pyrimidinderivater (f.eks. puriner) som proteinkinaseinhibitorer | |
| DE60332396D1 (de) | PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN | |
| DK1824856T3 (da) | 2,4 (4,6)-pyrimidinderivater | |
| DE602006007556D1 (de) | Heteroarylsulfonylstilbene als 5-ht2a-antagonisten | |
| ATE360632T1 (de) | Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate | |
| ATE432282T1 (de) | 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten | |
| ATE422198T1 (de) | Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten | |
| WO2005105803A3 (en) | Purine derivatives as a1 adenosine receptor antagonists | |
| ATE452892T1 (de) | Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate | |
| DE602004018637D1 (de) | A2a-adenosinrezeptorantagonisten | |
| ATE433977T1 (de) | Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido 1,2-a pyrimidin-4-on-derivate | |
| ATE471938T1 (de) | Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten | |
| IS7507A (is) | Ný efnasambönd | |
| ATE394402T1 (de) | Kondensierte purinderivate als a1- adenosinrezeptorantagonisten | |
| BRPI0512547A (pt) | pirimidinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1622908 Country of ref document: EP |